Lv01
0 积分 2022-01-12 加入
Historical Development of Monoclonal Antibody Therapeutics
8小时前
已完结
Monoclonal antibody therapeutics: history and future
8小时前
已完结
Current Strategy of Monoclonal Antibody: Development, Cloning, Formulation and Drug Delivery
9小时前
已完结
Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non–small-cell lung cancer: The global, multicenter EXPRESS study
7个月前
已完结
PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements
7个月前
已完结
Multi‐target angiogenesis inhibitor combined with PD‐1 inhibitors may benefit advanced non‐small cell lung cancer patients in late line after failure of EGFR‐TKI therapy
7个月前
已完结
Precision Immunotherapy for STK11/KEAP1-Mutant NSCLC
7个月前
已完结
Practical Considerations for the Use of Circulating Tumor DNA in the Treatment of Patients With Cancer
8个月前
已完结
POSing the question: MARIPOSA-2, do the ends justify the means?
8个月前
已完结
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial
8个月前
已完结
皖公网安备34019202002308
